Jazz Pharmaceuticals' (JAZZ) "Overweight" Rating Reiterated at Morgan Stanley

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report)'s stock had its "overweight" rating restated by investment analysts at Morgan Stanley in a report issued on Friday,Benzinga reports. They currently have a $183.00 price objective on the specialty pharmaceutical company's stock, up from their previous price objective of $175.00. Morgan Stanley's price objective points to a potential upside of 31.83% from the company's previous close.

JAZZ has been the topic of several other research reports. JPMorgan Chase & Co. upped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Barclays reissued an "overweight" rating and set a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Truist Financial upped their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research note on Thursday. Robert W. Baird upped their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a research note on Monday, November 18th. Finally, Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and upped their price objective for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $189.40.

Remove Ads

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ traded up $2.36 on Friday, hitting $138.81. The company's stock had a trading volume of 1,226,548 shares, compared to its average volume of 763,953. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $148.06. The company has a market capitalization of $8.43 billion, a price-to-earnings ratio of 19.55, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a 50 day moving average of $128.14 and a 200-day moving average of $120.03.

Insiders Place Their Bets

In other news, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the sale, the executive vice president now owns 33,318 shares of the company's stock, valued at $4,826,778.66. This represents a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Robert Iannone sold 7,080 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the sale, the chief marketing officer now directly owns 82,024 shares of the company's stock, valued at $11,368,526.40. The trade was a 7.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 25,193 shares of company stock valued at $3,533,122 over the last quarter. Company insiders own 4.20% of the company's stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several large investors have recently made changes to their positions in JAZZ. Fuller & Thaler Asset Management Inc. increased its position in shares of Jazz Pharmaceuticals by 117.4% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock worth $115,681,000 after acquiring an additional 507,234 shares in the last quarter. Darwin Global Management Ltd. acquired a new stake in Jazz Pharmaceuticals during the 4th quarter valued at $59,668,000. Dimensional Fund Advisors LP grew its holdings in Jazz Pharmaceuticals by 18.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after purchasing an additional 320,724 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Jazz Pharmaceuticals by 20.9% during the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock valued at $225,076,000 after purchasing an additional 315,608 shares in the last quarter. Finally, GMT Capital Corp grew its holdings in Jazz Pharmaceuticals by 140.0% during the 4th quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company's stock valued at $62,659,000 after purchasing an additional 296,800 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.